Black checkmark with a sparkle and a curved line underneath on a white background.
Company

OSR Holdings, Inc.

Ticker
OSRH
Sector
Industry
Report date
November 13, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent news coverage for OSR Holdings is limited but includes a significant $80 million stock purchase agreement signed with White Lion GBM Innovation Fund in April 2025.

Recent developments:
  • OSR Holdings signed an $80 million stock purchase agreement with White Lion GBM Innovation Fund, which was reported in April 2025 [N13].
Overview

OSR Holdings, Inc. operates as a global healthcare holding company with subsidiaries engaged in pharmaceutical and medical device innovation. Its business model centers on leveraging a network of academic and industry leaders to identify and support subsidiaries developing novel therapies, particularly oral T-cell immunotherapies and recombinant biologics. The company maintains a diversified portfolio to mitigate risks associated with single assets. Its subsidiaries hold multiple patents across key markets, supporting proprietary technologies. The lead subsidiary, Vaximm, has a late-stage clinical candidate for glioblastoma with orphan drug designations and several preclinical candidates targeting various tumor antigens. OSR Holdings pursues clinical development through phased trials and regulatory submissions, aiming to advance its pipeline efficiently. Financial disclosures as of Q3 2026 show limited liquidity and ongoing net losses, reflecting the developmental stage of its assets.

Executive summary

OSR Holdings, Inc. is a global healthcare holding company operating a hub-and-spoke model with subsidiaries focused on innovative pharmaceutical and medical device technologies, including oral T-cell immunotherapies. The company holds a substantial patent portfolio and is advancing clinical-stage and preclinical drug candidates, notably through its subsidiary Vaximm. Financially, as of September 30, 2026, OSR Holdings reported modest revenue and a net loss, with liquidity ratios indicating limited short-term asset coverage of liabilities. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for OSRH

Bull case model:

OSR Holdings benefits from a diversified portfolio of subsidiaries developing novel pharmaceutical and medical device technologies, reducing reliance on any single asset. Its lead clinical-stage candidate has orphan drug designations, which may provide regulatory exclusivity and competitive advantages. The company's extensive patent portfolio and collaborations with academic and industry leaders support its innovation pipeline. The hub-and-spoke business model enables efficient resource allocation and strategic alignment across subsidiaries. Recent financing agreements provide capital to support ongoing development activities.

Bear case model:

OSR Holdings faces challenges typical of early-stage healthcare holding companies, including limited liquidity as indicated by low current and cash ratios and ongoing net losses. The clinical and preclinical assets remain subject to regulatory, clinical, and commercial risks inherent in drug development. The company has limited operating history and depends on successful advancement of its subsidiaries' pipelines. Market and competitive risks, as well as potential delays or failures in clinical trials or regulatory approvals, could impact value creation. The company's financial position may constrain its ability to fund operations without additional capital.

Moat:

OSR Holdings' moat derives from its diversified portfolio of subsidiaries focused on innovative therapeutic technologies, supported by a substantial patent portfolio spanning multiple jurisdictions. The company's hub-and-spoke model facilitates centralized strategic oversight while empowering subsidiaries' specialized development efforts. Its lead clinical-stage asset benefits from orphan drug designations, providing regulatory exclusivity advantages. The company's network of academic and industry collaborators and its intellectual property rights create barriers to entry and support potential value creation through proprietary technology and clinical progress.

Risks overview
Risks summary
OSR Holdings' biggest risk is its limited liquidity combined with the inherent uncertainties of clinical development and regulatory approval processes, which may affect its ability to sustain operations and advance its pipeline.
Risks details:

• Liquidity Risk: As of September 30, 2026, OSR Holdings had a current ratio of 0.15 and a cash ratio of 0.08, indicating limited short-term asset coverage of liabilities, which may constrain operational flexibility [S2].
• Clinical Development Risk: The company's subsidiaries, including Vaximm, are advancing drug candidates through clinical trials that carry inherent risks of failure, delays, or regulatory challenges [S1].
• Regulatory Risk: Approval of drug candidates depends on successful completion of regulatory processes including IND applications, clinical trials, and NDA submissions, which are complex and uncertain [S1].
• Market and Competitive Risk: The healthcare and pharmaceutical markets are competitive and rapidly evolving, which may impact the commercial potential of the company's products and technologies [S1].

FINAL FORECAST FOR OSRH

Final take one line
OSR Holdings operates a diversified healthcare holding company model with substantial patent assets and clinical-stage subsidiaries but faces liquidity constraints and clinical development risks.
Final take 12 to 24 month view

Business trends: OSR Holdings continues to develop a diversified portfolio of innovative pharmaceutical and medical device subsidiaries, advancing clinical and preclinical drug candidates with orphan drug designations and patent protections.
Execution milestones: Progression through clinical trial phases, regulatory submissions including IND and NDA filings, and capital raising activities such as stock purchase agreements.
Key risks: Limited liquidity, clinical trial and regulatory uncertainties, and competitive market dynamics inherent in early-stage healthcare development.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • OSR Holdings, Inc. is a global healthcare holding company with operations in South Korea and Switzerland and an office in the United States [S1].
  • The company operates a hub-and-spoke business model with a centralized executive team partnering with subsidiary management teams to ensure alignment and value creation [S1].
  • OSR Holdings focuses on innovative pharmaceutical and medical device technologies through its subsidiaries, which have diverse scientific and technological developments including oral T-cell immunotherapies and recombinant biologics [S1].
  • The company owns or has in-licensed numerous patents and intellectual property, including 10 patent families with issued patents and pending applications in multiple jurisdictions, with expirations ranging from 2030 to 2041 [S1].
  • One subsidiary, Vaximm, develops oral T-cell immunotherapies targeting diseases such as glioblastoma and gastrointestinal stromal tumors, with a lead candidate VXM01 that has completed Phase 2 clinical trials and received Orphan Drug Designation from FDA and EMA [S1].
  • Vaximm is developing additional preclinical oral T-cell vaccine candidates targeting mesothelin, Wilms Tumor Protein, CEA, and PD-L1 [S1].
  • The company plans to advance its pipeline through preclinical studies, IND applications, and clinical trials, including Phase 2 and Phase 3 studies, followed by regulatory approval processes [S1].
  • As of September 30, 2026, OSR Holdings reported cash and equivalents of $1.37 million, current assets of $2.48 million, current liabilities of $16.68 million, resulting in a current ratio of 0.15 and a cash ratio of 0.08 [S2].
  • For the quarter ended September 30, 2026, the company reported revenue of $524,793 and a net loss of $1,614,147, with basic and diluted EPS of -$0.05 and -$0.15 respectively [S2].
  • The company signed an $80 million stock purchase agreement with White Lion GBM Innovation Fund in April 2025 [N13].
Sources
Sources - Context summary

Generated 2026-11-13

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-31 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-11-13 | www.nasdaq.com | BioStem Technologies, Inc. Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance | https://www.nasdaq.com/articles/biostem-technologies-inc-reports-third-quarter-2026-financial-results-and-raises-full-year
  • N2 | 2026-11-13 | www.nasdaq.com | Candel Therapeutics, Inc. Reports Third Quarter 2026 Financial Results and Plans Middle of 2027 BLA Submission for Aglatimagene | https://www.nasdaq.com/articles/candel-therapeutics-inc-reports-third-quarter-2026-financial-results-and-plans-middle-2027
  • N3 | 2026-11-13 | www.nasdaq.com | Hour Loop, Inc. Reports Results for Three and Nine Months Ended September 30, 2026 | https://www.nasdaq.com/articles/hour-loop-inc-reports-results-three-and-nine-months-ended-september-30-2026
  • N4 | 2026-11-13 | www.nasdaq.com | HiteJinro Earnings Up In Q3 | https://www.nasdaq.com/articles/hitejinro-earnings-q3
  • N5 | 2026-11-13 | www.nasdaq.com | GoPro, Inc. Enters Amendment No. 1 to Merger Agreement, Extending Outside Date to March 31, 2027 | https://www.nasdaq.com/articles/gopro-inc-enters-amendment-no-1-merger-agreement-extending-outside-date-march-31-2027
  • N6 | 2026-11-13 | www.nasdaq.com | Talphera, Inc. Reports Third Quarter 2026 Financial Results and Proposes Early Close of NEPHRO CRRT Study Enrollment | https://www.nasdaq.com/articles/talphera-inc-reports-third-quarter-2026-financial-results-and-proposes-early-close-nephro
  • N7 | 2026-11-13 | www.nasdaq.com | Nano-X Imaging Ltd. Enters into $50,000,000 Standby Equity Purchase Agreements with YA II PN, Ltd. | https://www.nasdaq.com/articles/nano-x-imaging-ltd-enters-50000000-standby-equity-purchase-agreements-ya-ii-pn-ltd
  • N8 | 2026-11-13 | www.nasdaq.com | Equillium Q3 Loss Widens On Higher R&D Expenses | https://www.nasdaq.com/articles/equillium-q3-loss-widens-higher-rd-expenses
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine